We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity, Inc. (RVTY - Free Report) reported second-quarter 2024 adjusted earnings per share (EPS) of $1.22, which beat the Zacks Consensus Estimate of $1.13 by 7.9%. The bottom line improved 0.8% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 59 cents compared with 47 cents in the prior-year period. However, GAAP EPS in the reported quarter was 45 cents, which includes a loss of 14 cents per share from discontinued operations.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $691.7 million, down 2% year over year and 1% organically. The top line missed the Zacks Consensus Estimate by 0.4%.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $313.8 million, indicating a decrease of 6.7% from the year-ago quarter’s level. Organically, the segment witnessed a decline of 6% year over year.
Adjusted operating income amounted to $112.4 million, down 12% from the prior-year quarter.
Diagnostics
This segment’s revenues totaled $378 million, up 1.4% on a year-over-year basis. Organically, the top line increased 3% year over year.
Adjusted operating income amounted to $97.9 million, up 14.9% from the year-ago quarter’s figure.
Selling, general and administrative expenses totaled $251.7 million, down 5.8% year over year. Research and development expenses amounted to $48.1 million, down 15.9% from the year-ago quarter’s reported number.
Adjusted operating income declined 2.7% to $198.9 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.7%, contracting 10 basis points.
Financial Update
The company exited the second quarter of 2024 with cash and cash equivalents of $1.95 billion compared with $1.70 billion in the prior-quarter end.
Net cash provided by operating activities, including discontinued operations, totaled $158.6 million compared with net cash used in operating activities of $135.3 million in the year-ago quarter.
2024 Guidance
Revvity raised its earnings and updated its revenue guidance for 2024.
For 2024, the company expects its adjusted EPS in the range of $4.70-$4.80. Revenues are anticipated to be in the band of $2.77-$2.79 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.64 per share and $2.80 billion, respectively.
Price Performance
RVTY’s shares have gained 3.6% in the past six months compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.9% in the same period.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
RVTY carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Boston Scientific Corporation (BSX - Free Report) , Hologic (HOLX - Free Report) and Universal Health Services (UHS - Free Report) .
Boston Scientific reported first-quarter 2024 adjusted earnings per share of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.5%.
Hologic, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.
Hologic’s shares have risen 0.3% year to date compared with the industry’s 4.7% growth.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
Revvity, Inc. (RVTY - Free Report) reported second-quarter 2024 adjusted earnings per share (EPS) of $1.22, which beat the Zacks Consensus Estimate of $1.13 by 7.9%. The bottom line improved 0.8% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 59 cents compared with 47 cents in the prior-year period. However, GAAP EPS in the reported quarter was 45 cents, which includes a loss of 14 cents per share from discontinued operations.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $691.7 million, down 2% year over year and 1% organically. The top line missed the Zacks Consensus Estimate by 0.4%.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $313.8 million, indicating a decrease of 6.7% from the year-ago quarter’s level. Organically, the segment witnessed a decline of 6% year over year.
Adjusted operating income amounted to $112.4 million, down 12% from the prior-year quarter.
Diagnostics
This segment’s revenues totaled $378 million, up 1.4% on a year-over-year basis. Organically, the top line increased 3% year over year.
Adjusted operating income amounted to $97.9 million, up 14.9% from the year-ago quarter’s figure.
Revvity Inc. Price, Consensus and EPS Surprise
Revvity Inc. price-consensus-eps-surprise-chart | Revvity Inc. Quote
Margin Analysis
Selling, general and administrative expenses totaled $251.7 million, down 5.8% year over year. Research and development expenses amounted to $48.1 million, down 15.9% from the year-ago quarter’s reported number.
Adjusted operating income declined 2.7% to $198.9 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.7%, contracting 10 basis points.
Financial Update
The company exited the second quarter of 2024 with cash and cash equivalents of $1.95 billion compared with $1.70 billion in the prior-quarter end.
Net cash provided by operating activities, including discontinued operations, totaled $158.6 million compared with net cash used in operating activities of $135.3 million in the year-ago quarter.
2024 Guidance
Revvity raised its earnings and updated its revenue guidance for 2024.
For 2024, the company expects its adjusted EPS in the range of $4.70-$4.80. Revenues are anticipated to be in the band of $2.77-$2.79 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.64 per share and $2.80 billion, respectively.
Price Performance
RVTY’s shares have gained 3.6% in the past six months compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.9% in the same period.
Image Source: Zacks Investment Research
Zacks Rank & Stocks to Consider
RVTY carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are Boston Scientific Corporation (BSX - Free Report) , Hologic (HOLX - Free Report) and Universal Health Services (UHS - Free Report) .
Boston Scientific reported first-quarter 2024 adjusted earnings per share of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.5%.
Hologic, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.
Hologic’s shares have risen 0.3% year to date compared with the industry’s 4.7% growth.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank of 2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%.